Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 11,335

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Pharmacological interventions for somatoform disorders in adults

Open access
Kleinstäuber, Maria, Witthöft, Michael, Steffanowski, Andrés, van Marwijk, Harm, Hiller, Wolfgang, Lambert, Michael J·2014·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd010628.pub2
Open this paper in CoChat — free account

Abstract

BACKGROUND: Somatoform disorders are characterised by chronic, medically unexplained physical symptoms (MUPS). Although different medications are part of treatment routines for people with somatoform disorders in clinics and private practices, there exists no systematic review or meta-analysis on the efficacy and tolerability of these medications. We aimed to synthesise to improve optimal treatment decisions. OBJECTIVES: To assess the effects of pharmacological interventions for somatoform disorders (specifically somatisation disorder, undifferentiated somatoform disorder, somatoform autonomic dysfunction, and pain disorder) in adults. SEARCH METHODS: We searched the Cochrane Depression, Anxiety and Neurosis Review Group's Specialised Register (CCDANCTR) (to 17 January 2014). This register includes relevant randomised controlled trials (RCTs) from The Cochrane Library (all years), MEDLINE (1950 to date), EMBASE (1974 to date), and PsycINFO (1967 to date). To identify ongoing trials, we searched ClinicalTrials.gov, Current Controlled Trials metaRegister, the World Health Organization International Clinical Trials Registry Platform, and the Chinese Clinical Trials Registry. For grey literature, we searched ProQuest Dissertation & Theses Database, OpenGrey, and BIOSIS Previews. We handsearched conference proceedings and reference lists of potentially relevant papers and systematic reviews and contacted experts in the field. SELECTION CRITERIA: We selected RCTs or cluster RCTs of pharmacological interventions versus placebo, treatment as usual, another medication, or a combination of different medications for somatoform disorders in adults. We included people fulfilling standardised diagnostic criteria for somatisation disorder, undifferentiated somatoform disorder, somatoform autonomic dysfunction, or somatoform pain disorder. DATA COLLECTION AND ANALYSIS: One review author and one research assistant independently extracted data and assessed risk of bias. Primary outcomes included the severity of MUPS on a continuous measure, and acceptability of treatment. MAIN RESULTS: We included 26 RCTs (33 reports), with 2159 participants, in the review. They examined the efficacy of different types of antidepressants, the combination of an antidepressant and an antipsychotic, antipsychotics alone, or natural products (NPs). The duration of the studies ranged between two and 12 weeks.One meta-analysis of placebo-controlled studies showed no clear evidence of a significant difference between tricyclic antidepressants (TCAs) and placebo for the outcome severity of MUPS (SMD -0.13; 95% CI -0.39 to 0.13; 2 studies, 239 participants; I(2) = 2%; low-quality evidence). For new-generation antidepressants (NGAs), there was very low-quality evidence showing they were effective in reducing the severity of MUPS (SMD -0.91; 95% CI -1.36 to -0.46; 3 studies, 243 participants; I(2) = 63%). For NPs there was low-quality evidence that they were effective in reducing the severity of MUPS (SMD -0.74; 95% CI -0.97 to -0.51; 2 studies, 322 participants; I(2) = 0%).One meta-analysis showed no clear evidence of a difference between TCAs and NGAs for severity of MUPS (SMD -0.16; 95% CI -0.55 to 0.23; 3 studies, 177 participants; I(2) = 42%; low-quality evidence). There was also no difference between NGAs and other NGAs for severity of MUPS (SMD -0.16; 95% CI -0.45 to 0.14; 4 studies, 182 participants; I(2) = 0%).Finally, one meta-analysis comparing selective serotonin reuptake inhibitors (SSRIs) with a combination of SSRIs and antipsychotics showed low-quality evidence in favour of combined treatment for severity of MUPS (SMD 0.77; 95% CI 0.32 to 1.22; 2 studies, 107 participants; I(2) = 23%).Differences regarding the acceptability of the treatment (rate of all-cause drop-outs) were neither found between NGAs and placebo (RR 1.01, 95% CI 0.64 to 1.61; 2 studies, 163 participants; I(2) = 0%; low-quality evidence) or NPs and placebo (RR 0.85, 95% CI 0.40 to 1.78; 3 studies, 506 participants; I(2) = 0%; low-quality evidence); nor between TCAs and other medication (RR 1.48, 95% CI 0.59 to 3.72; 8 studies, 556 participants; I(2) =14%; low-quality evidence); nor between antidepressants and the combination of an antidepressant and an antipsychotic (RR 0.80, 95% CI 0.25 to 2.52; 2 studies, 118 participants; I(2) = 0%; low-quality evidence). Percental attrition rates due to adverse effects were high in all antidepressant treatments (0% to 32%), but low for NPs (0% to 1.7%).The risk of bias was high in many domains across studies. Seventeen trials (65.4%) gave no information about random sequence generation and only two (7.7%) provided information about allocation concealment. Eighteen studies (69.2%) revealed a high or unclear risk in blinding participants and study personnel; 23 studies had high risk of bias relating to blinding assessors. For the comparison NGA versus placebo, there was relatively high imprecision and heterogeneity due to one outlier s

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd010628.pub2

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 173

  1. Altamura, 1991, L-sulpiride in the treatment of somatoform disturbances: a double-blind study with racemic sulpiride, Minerva Psichiatrica, 32, 25
  2. Aragona, 2005, Randomized double-blind comparison of serotonergic (citalopram) versus noradrenergic (reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder, European Journal of Pain, 9, 33, 10.1016/j.ejpain.2004.03.003 · DOI
  3. Eberhard, 1988, A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes, Neuropsychobiology, 19, 25, 10.1159/000118429 · DOI
  4. Han, 2008, Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: a 12-week prospective, open-label, randomized, parallel-group trial, Clinical Drug Investigation, 28, 251, 10.2165/00044011-200828040-00006 · DOI
  5. Han, 2008, Fluoxetine versus sertraline in the treatment of patients with undifferentiated somatoform disorder: a randomized, open-label, 12-week, parallel-group trial, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 32, 437, 10.1016/j.pnpbp.2007.09.014 · DOI
  6. Huang, 2012, Combination of citalopram plus paliperidone is better than citalopram alone in the treatment of somatoform disorder: results of a 6-week randomized study, International Clinical Psychopharmacology, 27, 151, 10.1097/YIC.0b013e328351c7e8 · DOI
  7. Jiang, 2005, A clinical effective analysis of venlafaxine in treatment of somatoform disorders, Chinese General Practice, 8, 1177
  8. Ju, 2003, A study of venlafaxine in the treatment of somatization disorder, Medical Journal of Chinese People's Health, 15, 590
  9. Kong, 2004, Comparison study of domestic paroxetine and amitriptyline in treatment of somatoform disorders randomized double-blind study, Medical Journal of Chinese People's Health, 10, 733-4, 742
  10. Kroenke, 2004, Short-term treatment of depressed and anxious primary care patients with multiple, unexplained somatic symptoms: a pilot study, Neuropsychopharmacology, 29, S210
  11. Kroenke, 2006, Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder, Journal of Clinical Psychiatry, 67, 72, 10.4088/JCP.v67n0111 · DOI
  12. Li, 2006, Comparison study of paroxetine and paroxetine combined with quetiapine in treatment of somatoform disorder, Chinese Journal of Behavioral Medical Science, 15, 598
  13. Luo, 2009, A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 1522, 10.1016/j.pnpbp.2009.08.013 · DOI
  14. Kraft, 2010, Additional benefit of Petasites hybridus (butterbur) in a four-combination for somatoform disorders, Focus on Alternative and Complementary Therapies, 15, 25, 10.1211/fact.15.1.0012 · DOI
  15. Melzer, 2012, Results of a randomized, placebo-controlled pharmaco-clinical study with a combined herbal preparation for the treatment of patients with somatoform disorders, Schweizerische Zeitschrift für Ganzheitsmedizin, 24, 284, 10.1159/000342466 · DOI
  16. Melzer J Schrade E Brattström A Schellenberg R Saller R Herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatization disorders: randomized, placebo-controlled pharmaco-clinical trial Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Neurologie (DGPPN) Congress; 2009 Nov 25-28; Berlin, Germany 2009 · DOI
  17. Melzer, 2009, Fixed herbal drug combination with and without butterbur (Ze 185) for the treatment of patients with somatoform disorders: randomized, placebo-controlled pharmaco-clinical trial, Phytotherapy Research, 23, 1303, 10.1002/ptr.2771 · DOI
  18. Müller, 2004, Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial, Psychosomatic Medicine, 66, 538, 10.1097/01.psy.0000128900.13711.5b · DOI
  19. Müller, 2008, Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial, International Clinical Psychopharmacology, 23, 43, 10.1097/YIC.0b013e32825ea301 · DOI
  20. Ouyang, 2006, Comparison of mirtazapine and amitriptyline in the treatment of somatoform disorders, Chinese Journal of Health Psychology, 14, 560
  21. Pilowsky, 1990, A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable 'psychogenic' pain, Pain, 40, 3, 10.1016/0304-3959(90)91045-K · DOI
  22. Sanada, 2010, Comparison of effect of paroxetine and milnacipran for outpatients with pain disorder conference abstract, European Neuropsychopharmacology, 20 Suppl 3, S543, 10.1016/S0924-977X(10)70817-8 · DOI
  23. Möller, 2003, Psychopharmacotherapy of somatoform disorders: effects of opipramol on symptoms of somatization, anxiety, and depression, Acta Neuropsychiatrica, 15, 217, 10.1034/j.1601-5215.2003.00030.x · DOI
  24. Volz, 2000, Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial, European Neuropsychopharmacology, 10, 211, 10.1016/S0924-977X(00)00074-2 · DOI
  25. Anonymus, 2003, St. John's wort effective for somatoform disorders independent of depressive symptoms, Brown University Psychopharmacology Update, 14, 3
  26. Murck, 2002, St. John's wort extract (LI 160) in somatoform disorders - results of a placebo-controlled trial, European Neuropsychopharmacology, 12, S342, 10.1016/S0924-977X(02)80536-3 · DOI
  27. Volz, 2003, St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Erratum, Psychopharmacology, 167, 333, 10.1007/s00213-003-1420-3 · DOI
  28. Volz, 2002, St John's wort extract (li 160) in somatoform disorders: results of a placebo-controlled trial, Psychopharmacology, 164, 294, 10.1007/s00213-002-1171-6 · DOI
  29. Wang, 2003, A double-blind study on trazodone in the treatment of persistent somatoform pain disorder, Chinese Journal of Pain Medicine, 9, 70
  30. Xu, 2004, Venlafaxine in the treatment of 35 cases of persistent somatoform pain disorder, Herald of Medicine, 23, 397
  31. Yang, 2006, A control study of venlafaxine in the treatment of somatoform disorder, Journal of Clinical Psychosomatic Diseases, 12, 262
  32. Ye, 2006, Mirtazapine in treatment of somatization disorder, Clinical Medicine, 16, 14
  33. Zhao, 2006, A controlled study of mirtazapine and amitriptyline in somatization, Evaluation and Analysis of Drug-Use in Hospitals of China, 6, 175
  34. Zitman, 1991, Does addition of low-dose flupenthixol enhance the analgesic effects of low-dose amitriptyline in somatoform pain disorder?, Pain, 47, 25, 10.1016/0304-3959(91)90007-K · DOI
  35. Altamura, 2003, Levosulpiride in somatoform disorders: a double-blind, placebo-controlled cross-over study, International Journal of Psychiatry in Clinical Practice, 7, 155, 10.1080/13651500310001833 · DOI
  36. Ballbe, 1970, Action of WY 3498 in hysteria and anxiety neuroses, Prensa medica argentina, 58, 946
  37. Bratfos, 1967, Symptomatic relief of neurotic symptoms with tybamate: a double-blind, placebo-controlled study, Acta Psychiatrica Scandinavica, 43, 282, 10.1111/j.1600-0447.1967.tb05765.x · DOI
  38. Cui, 2004, A controlled study of the treatment of electric acupuncture and low dose perphenazine on hysteria, Chinese Journal of the Practical Chinese with Modern Medicine, 4, 2928
  39. Davis, 1988, Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study, Digestive Diseases and Sciences, 33, 1505, 10.1007/BF01535938 · DOI
  40. Fukuda, 1971, Comparative evaluation of the effect on the psychosomatic symptoms between medazepam (s-804) and diazepam by means of double blind method, Modern Medicine, 26, 1564
  41. Hasegawa, 1977, The clinical efficacy of id-540, a psychotropic drug, for psychosomatic disease and neurosis: double-blind comparative study, Rinsyotokenkyu, 54, 2075
  42. Holdevici, 1995, The suggestive action of some 'placebo' medications in the balancing of patients with somatoform disorders, Revue Roumaine de Psychologie, 39, 129
  43. Kozian, 2003, Olanzapin in the therapy of a somatoform disorder, Fortbildung und Diskussion, 30, 450
  44. Lee JH Kim B Kang EH Yu BH Anti-stress effect of Korean red ginseng (Panax ginseng C.A. Mayer) in healthy individuals with medically unexplained stress-related somatic symptoms: a randomized, double-blind, and placebo controlled clinical study. Proceedings of the 15th Pacific Rim College of Psychiatrists Scientific Meeting; 2012 Oct 25-27; Seoul, Korea 2012
  45. Loldrup, 1989, Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study, Psychopharmacology, 99, 1, 10.1007/BF00634443 · DOI
  46. Onghena, 1993, Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study, Acta Psychiatrica Scandinavica, 88, 198, 10.1111/j.1600-0447.1993.tb03439.x · DOI · Paper page
  47. Pach, 1976, A comparison of the tranquilizing effect of fluspirilene and diazepam, Pharmakopsychiatrie, Neuro-Psychopharmakologie, 9, 61, 10.1055/s-0028-1094479 · DOI
  48. Poinso, 1988, A multicentre double-blind trial of sulpiride versus toloxatone in patients with reactive depressions and somatization receiving non-specialized care, Semaine des hopitaux, 64, 1201
  49. Raich, 1966, A double-blind evaluation of fenfluramine in anxious somatizing neurotic medical clinic patients., Current Therapeutic Research, Clinical and Experimenta, 8, 31
  50. Smith, 1971, A controlled comparative study of doxepin and chlordiazepoxide in psychoneurotic anxiety, Journal of Clinical Pharmacology & New Drugs, 11, 152, 10.1177/009127007101100211 · DOI
  51. Tanum, 1996, A new pharmacologic treatment of functional gastrointestinal disorder: a double-blind placebo-controlled study with mianserin, Scandinavian Journal of Gastroenterology, 31, 318, 10.3109/00365529609006404 · DOI
  52. Tsutsui, 1984, The clinical efficacy of brotizolam (we941), a hypnotic, by the double-blind method in the field of internal medicine (psychosomatic medicine), geriatric medicine, Journal of Clinical and Experimental Medicine, Medicine in Progress, 131, 412
  53. Tsutsui, 1985, The clinical evaluation of efficacy and safety of brotizolam (we 941), a hypnotic, in the fields of internal medicine and psychosomatic medicine: A comparative study by the double-blind method, Medical Consultation & New Remedies, 22, 41
  54. Tsutsui, 1986, The clinical evaluation of lormetazepam, a new hypnotic, in the field of internal medicine, psychosomatic medicine: a double-blind comparative study with haloxazolam, Japanese Journal of Clinical and Experimental medicine, 63, 1627
  55. Tsutsui, 1987, Multi-center double-blind clinical trial on 450191-s, a new hypnotic, in the field of psychosomatic medicine, Clinical Report, 1, 3683
  56. Tsutsui, 1992, Dose-finding study of sch161 in the field of psychosomatic medicine: double-blind comparative study with placebo, Journal of Clinical Therapeutics and Medicine, 8, 335
  57. Turkington, 2002, A randomized controlled trial of fluvoxamine in prostatodynia, a male somatoform pain disorder, Journal of Clinical Psychiatry, 63, 778, 10.4088/JCP.v63n0905 · DOI
  58. Xu, 2006, A comparative study of paroxetine versus acupuncture-therapy in treatment of somatization disorder, Journal of Practical Medical Techniques, 13, 2302
  59. Zang, 1991, A self body double blind clinical study of L-tryptophan and placebo in treated neurosis, Chinese Journal of Neurology and Psychiatry, 24, 77
  60. Zhao, 1989, A self-body double-blind trial of L-tryptophan in neurosis and depression, Acta Academiae Medicinae Hubei, 10, 256
  61. Zitman, 1990, Low-dose amitriptyline in chronic pain: the gain is modest, Pain, 42, 35, 10.1016/0304-3959(90)91089-2 · DOI
  62. Agger, 2013, Pharmacological treatment of multi-organ bodily distress syndrome: a double-blind, placebo-controlled trial of the effects of imipramine (STreSS-3), Journal of Psychosomatic Research, 75, 196, 10.1016/j.jpsychores.2013.06.024 · DOI
  63. Allen, 2002, Psychosocial treatments for multiple unexplained physical symptoms: a review of literature, Psychosomatic Medicine, 64, 393
  64. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders (DSM III)
  65. American Psychiatric Association, 1994, Diagnostic and Statistical Manual for Mental Disorders (DSM IV)
  66. American Psychiatric Association, 2013, Diagnostic and Statistical Manual of Mental Disorders (DSM III).
  67. Atkinson, 1985, Psychopharmacological agents in the treatment of pain, Journal of Bone and Joint Surgery - American Volume, 67A, 337
  68. Barsky, 2005, Somatization increases medical utilization and costs independent of psychiatric and medical comorbidity, Archives of General Psychiatry, 62, 903, 10.1001/archpsyc.62.8.903 · DOI · Paper page
  69. Beck, 1990, Beck Anxiety Inventory Manual
  70. Bergin, 1971, The evaluation of therapeutic outcomes, 217
  71. Bonaz, 2002, Central processing of rectal pain in patients with irritable bowel syndrome: an fMRI study, American Journal of Gastroenterology, 97, 654, 10.1111/j.1572-0241.2002.05545.x · DOI
  72. Butterweck, 2003, Mechanism of action of St John's wort in depression - what is known?, CNS Drugs, 17, 539, 10.2165/00023210-200317080-00001 · DOI · Paper page
  73. Chinese Society of Psychiatry, 2001, The Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CCMD-3)
  74. Clayton, 2005, Gender differences in clinical psychopharmacology, Journal of Clinical Psychiatry, 66, 1191, 10.4088/JCP.v66n0916 · DOI
  75. Creed, 2011, Epidemiology: prevalence, causes and consequences, 10.1017/CBO9780511977862.002 · DOI
  76. Waal, 2004, Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders, British Journal of Psychiatry, 184, 470, 10.1192/bjp.184.6.470 · DOI · Paper page
  77. Decoutere, 2011, Antipsychotic agents in the treatment of somatoform disorders: a review, Tijdschrift voor Psychiatrie, 53, 163
  78. Derogatis, 1983, The SCL-90-R Manual. Scoring and Administration Procedures for the SCL-90-R
  79. Derogatis, 1992, The Brief Symptom Inventory (BSI): Administration, Scoring, and Procedures Manual II
  80. Franco, 2010, Pharmacological treatment of fibromyalgia, Clinical and Experimental Rheumatology, 28, S110
  81. Escobar, 1987, Somatization in the community, Archives of General Psychiatry, 44, 713, 10.1001/archpsyc.1987.01800200039006 · DOI · Paper page
  82. Escobar, 1996, Pharmacological treatment of somatization/hypochondriasis, Psychopharmacology Bulletin, 32, 589
  83. Fallon, 2004, Pharmacotherapy of somatoform disorders, Journal of Psychosomatic Research, 56, 455, 10.1016/S0022-3999(03)00631-7 · DOI
  84. Fishbain, 1998, Do antidepressants have an analgesic effect in psychogenic pain and somatoform pain disorder? A meta-analysis, Psychosomatic Medicine, 60, 503, 10.1097/00006842-199807000-00019 · DOI
  85. Fröhlich, 2006, DSM-IV pain disorder in the general population - an exploration of the structure and threshold of medically unexplained pain symptoms, European Archives of Psychiatry and Clinical Neuroscience, 256, 187, 10.1007/s00406-005-0625-3 · DOI
  86. Gamble, 2005, Uncertainty method improved on best-worst case analysis in a binary meta-analysis, Journal of Clinical Epidemiology, 58, 579, 10.1016/j.jclinepi.2004.09.013 · DOI
  87. Gildenberg, 1984, Management of chronic pain, Applied Neurophysiology, 47, 157
  88. Grabe, 2003, Specific somatoform disorder in the general population, Psychosomatics, 44, 304, 10.1176/appi.psy.44.4.304 · DOI
  89. Grothe, 2004, Treatment of pain syndromes with venlafaxine, Pharmacotherapy, 24, 621, 10.1592/phco.24.6.621.34748 · DOI
  90. Gu, 2002, Gabapentin potentiates N-methyl-D-aspartate receptor mediated currents in rat GABAergic dorsal horn neurons, Neuroscience Letters, 324, 177, 10.1016/S0304-3940(02)00160-X · DOI
  91. Gureje, 2004, What can we learn from a cross-national study of somatic distress?, Journal of Psychosomatic Research, 56, 409, 10.1016/S0022-3999(03)00623-8 · DOI
  92. Guy, 1976, Clinical Global Impressions, 218
  93. Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
  94. Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  95. Hoedeman, 2010, Consultation letters for medically unexplained physical symptoms in primary care, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006524.pub2 · DOI
  96. Huertas-Ceballos, 2014, Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003017.pub3 · DOI
  97. Ipser, 2009, Pharmacotherapy and psychotherapy for body dysmorphic disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005332.pub2 · DOI
  98. Jackson, 2000, Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis, American Journal of Medicine, 108, 65, 10.1016/S0002-9343(99)00299-5 · DOI · Paper page
  99. Jackson, 2006, Antidepressants and cognitive-behavioral therapy for symptom syndromes, CNS Spectrums, 11, 212, 10.1017/S1092852900014383 · DOI
  100. Jackson, 2006, Managing somatization: medically unexplained should not mean medically ignored, Journal of General Internal Medicine, 21, 797, 10.1111/j.1525-1497.2006.00514.x · DOI
  101. Janca, 1996, CD-10 Checklists - a tool for clinicians' use of the ICD-10 classification of mental and behavioral disorders, Comprehensive Psychiatry, 37, 180, 10.1016/S0010-440X(96)90034-6 · DOI
  102. Johansson, 1982, Patients with Chronic Pain. A Clinical, Clinical-pharmacological and Biochemical Study [medical dissertation]
  103. Jones, 1991, Descending noradrenergic influences on pain, Progress in Brain Research, 88, 381, 10.1016/S0079-6123(08)63824-8 · DOI · Paper page
  104. Kellner, 1986, Somatization and Hypochondriasis
  105. Kirmayer, 1997, Somatoform disorders, 420
  106. Kroenke, 1997, Multisomatoform disorder. An alternative to undifferentiated somatoform disorder for the somatizing patient in primary care, Archives of General Psychiatry, 54, 352, 10.1001/archpsyc.1997.01830160080011 · DOI · Paper page
  107. Kroenke, 2002, The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms, Psychosomatic Medicine, 64, 258, 10.1097/00006842-200203000-00008 · DOI · Paper page
  108. Kubera, 2001, Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio, Journal of Clinical Psychopharmacology, 21, 199, 10.1097/00004714-200104000-00012 · DOI · Paper page
  109. Lambert, 1994, Assessing psychotherapy outcomes and process, 72
  110. Leiknes, 2007, Course and predictors of medically unexplained pain symptoms in the general population, Journal of Psychosomatic Research, 62, 119, 10.1016/j.jpsychores.2006.08.009 · DOI
  111. Linde, 2009, St. John's wort - an overview, Forschende Komplementärmedizin, 16, 146, 10.1159/000209290 · DOI
  112. Lipman, 1969, Factors of symptom distress. Doctor ratings of anxious neurotic outpatients, Archives of General Psychiatry, 21, 328, 10.1001/archpsyc.1969.01740210072009 · DOI
  113. Loder, 2004, Off-label prescribing of drugs in specialty headache practice, Headache, 44, 636, 10.1111/j.1526-4610.2004.04121.x · DOI
  114. Lynch, 2001, Antidepressants as analgesics: a review of randomized controlled trials, Journal of Psychiatry & Neuroscience, 26, 30
  115. Maes, 2001, The immunoregulatory effects of antidepressants, Human Psychopharmacology - Clinical and Experimental, 16, 95, 10.1002/hup.191 · DOI
  116. Magni, 1991, The use of antidepressants in the treatment of chronic pain: a review of the current evidence, Drugs, 42, 730, 10.2165/00003495-199142050-00002 · DOI
  117. Marks, 2009, Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise, Current Neuropharmacology, 7, 331, 10.2174/157015909790031201 · DOI
  118. Mcquay, 1995, Anticonvulsant drugs for management of pain: a systematic review, BMJ, 311, 1047, 10.1136/bmj.311.7012.1047 · DOI · Paper page
  119. Melzack, 1987, The short-form McGill Pain Questionnaire, Pain, 30, 191, 10.1016/0304-3959(87)91074-8 · DOI · Paper page
  120. Meyer, 2001, Prevalence of DSM-IV psychiatric disorders including nicotine dependence in the general population: results from the Northern German TACOS study, Neurology Psychiatry and Brain Research, 9, 75
  121. Montoya, 2005, Altered processing of pain-related information in patients with fibromyalgia, European Journal of Pain, 9, 293, 10.1016/j.ejpain.2004.07.012 · DOI
  122. Moore, 2009, Pregabalin for acute and chronic pain in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007076.pub2 · DOI · Paper page
  123. Moore, 2011, Gabapentin for chronic neuropathic pain and fibromyalgia in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD007938.pub2 · DOI · Paper page
  124. Mumford, 1991, The Bradford Somatic Inventory - a multiethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan subcontinent, British Journal of Psychiatry, 158, 379, 10.1192/bjp.158.3.379 · DOI
  125. Naliboff, 1997, Evidence for two distinct perceptual alterations in irritable bowel syndrome, Gut, 41, 505, 10.1136/gut.41.4.505 · DOI · Paper page
  126. Nix, 1998, What is certain in pain therapy? The analgesic potency of neuroleptics in the treatment of chronic pain. A meta-analysis, Schmerz, 12, 30, 10.1007/s004820050125 · DOI
  127. O'Malley, 1999, Antidepressant therapy for unexplained medical symptoms and syndromes, Journal of Family Practice, 48, 980
  128. Pae, 2009, Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants, Expert Opinion on Pharmacotherapy, 10, 1561, 10.1517/14656560902988510 · DOI
  129. Petzke, 2005, Differences in unpleasantness induced by experimental pressure pain between patients with fibromyalgia and healthy controls, European Journal of Pain, 9, 325, 10.1016/j.ejpain.2004.09.001 · DOI
  130. Price, 2000, Review: antidepressants are effective for clinical unexplained symptoms and syndromes, Evidence Based Mental Health, 3, 84, 10.1136/ebmh.3.3.84 · DOI
  131. Prior, 2013, Somatic symptom disorders and illness behaviour: current perspectives, International Review of Psychiatry, 25, 5, 10.3109/09540261.2012.732043 · DOI
  132. Raine, 2002, Systematic review of mental health interventions for patients with common somatic symptoms: can research evidence from secondary care be extrapolated to primary care?, BMJ, 325, 1082, 10.1136/bmj.325.7372.1082 · DOI
  133. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012
  134. Richardson, 1990, Serotonin and nociception, Annals of the New York Academy of Sciences, 600, 511, 10.1111/j.1749-6632.1990.tb16906.x · DOI
  135. Rickels, 1994, Evaluating drug treatments of generalized anxiety disorder and adjustment disorders with anxious mood, 373
  136. Rief, 1998, Cognitive aspects of hypochondriasis and the somatization syndrome, Journal of Abnormal Psychology, 107, 587, 10.1037/0021-843X.107.4.587 · DOI · Paper page
  137. Rief, 1999, Toward empirically based criteria for the classification of somatoform disorders, Journal of Psychosomatic Research, 46, 507, 10.1016/S0022-3999(99)00023-9 · DOI
  138. Rief, 2003, A new approach to assess illness behaviour, Journal of Psychosomatic Research, 54, 405, 10.1016/S0022-3999(02)00401-4 · DOI
  139. Rief, 2005, Psychobiological perspectives on somatoform disorders, Psychoneuroendocrinology, 30, 996, 10.1016/j.psyneuen.2005.03.018 · DOI · Paper page
  140. Rief, 2007, Explaining medically unexplained physical symptoms - models and mechanisms, Clinical Psychology Review, 27, 821, 10.1016/j.cpr.2007.07.005 · DOI · Paper page
  141. Rief, 2008, SOMS Screening for Somatoform Disorders [SOMS Das Screening für Somatoforme Störungen. Manual zum Fragebogen]
  142. Robins, 1991, Psychiatric Disorders in America: The Epidemiological Catchment Area Study
  143. Ruddy, 2005, Psychosocial interventions for conversion disorder, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005331.pub2 · DOI
  144. Ryder, 2008, The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America?, Journal of Abnormal Psychology, 117, 300, 10.1037/0021-843X.117.2.300 · DOI · Paper page
  145. Saarto, 2007, Antidepressants for neuropathic pain, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005454.pub2 · DOI · Paper page
  146. Satterthwaite, 1990, The use of tricyclic antidepressants for the treatment of intractable pain, Comprehensive Therapy, 16, 10
  147. Schreiber, 1999, The atypical neuroleptics clozapine and olanzapine differ regarding their antinociceptive mechanisms and potency, Pharmacology Biochemistry and Behavior, 64, 75, 10.1016/S0091-3057(99)00107-0 · DOI
  148. Schünemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  149. Seidel, 2008, Antipsychotics for acute and chronic pain in adults, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004844.pub2 · DOI
  150. Sharma, 2013, Behavioural and psychological management of somatic symptom disorders: an overview, International Review of Psychiatry, 25, 116, 10.3109/09540261.2012.746649 · DOI
  151. Sharpe, 1995, Concepts, theories and terminology, 3, 10.1093/oso/9780192624994.003.0001 · DOI
  152. Sheehan, 1983, The Anxiety Disease
  153. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, Journal of Clinical Psychiatry, 59, 22
  154. Silberstein, 2002, Olanzapine in the treatment of refractory migraine and chronic daily headache, Headache, 42, 515, 10.1046/j.1526-4610.2002.02126.x · DOI
  155. Somashekar, 2013, Psychopharmacotherapy of somatic symptoms disorders. Review, International Review of Psychiatry, 25, 107, 10.3109/09540261.2012.729758 · DOI
  156. Sommer, 1993, Placebo-controlled double-blind study examining the effectiveness of an Hypericum preparation in 105 patients with depressions, Nervenheilkunde, 12, 274
  157. Stahl, 2002, The psychopharmacology of painful physical symptoms in depression, Journal of Clinical Psychiatry, 63, 382, 10.4088/JCP.v63n0501 · DOI
  158. Sterne JAC Egger M Moher D Chapter 10: Addressing reporting bias. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
  159. Stone, 2003, Off-label applications for SSRIs, American Family Physician, 68, 498
  160. Suls, 2012, Understanding the physical-symptom experience: the distinctive contributions of anxiety and depression, Current Directions in Psychological Science, 21, 129, 10.1177/0963721412439298 · DOI
  161. Sumathipala, 2007, What is the evidence for the efficacy of treatments for somatoform disorders? A critical review of previous intervention studies, Psychosomatic Medicine, 69, 889, 10.1097/PSY.0b013e31815b5cf6 · DOI
  162. Urban, 2005, Comparison of the antinociceptive profiles of gabapentin and 3-methylgabapentin in rat models of acute and persistent pain: implications for mechanism of action, Journal of Pharmacology and Experimental Therapeutics, 31, 1209, 10.1124/jpet.104.081778 · DOI
  163. Ursin, 1997, Sensitization, somatization, and subjective health complaints, International Journal of Behavioral Medicine, 4, 105, 10.1207/s15327558ijbm0402_1 · DOI
  164. Verdu, 2008, Antidepressants for the treatment of chronic pain, Drugs, 68, 2611, 10.2165/0003495-200868180-00007 · DOI
  165. Verhaak, 2006, Persistent presentation of medically unexplained symptoms in general practice, Family Practice, 23, 414, 10.1093/fampra/cml016 · DOI
  166. Volz, 2003, St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Erratum, Psychopharmacology, 167, 333, 10.1007/s00213-003-1420-3 · DOI
  167. World Health Organization, 1975, International Classification of Diseases. 9th revision (ICD-9)
  168. World Health Organization, 1992, International Statistical Classification of Diseases. 10th Revision (ICD-10)
  169. Williams, 1982, Idiopathic pain disorder: a critique of pain-prone disorder and a proposal for a revision of the DSM-III category psychogenic pain disorder, Journal of Nervous and Mental Disease, 170, 415, 10.1097/00005053-198207000-00005 · DOI
  170. Wittchen, 1992, Lifetime and 6-month prevalence of mental disorders in the Munich follow-up-study, European Archives of Psychiatry and Clinical Neuroscience, 241, 247, 10.1007/BF02190261 · DOI · Paper page
  171. Witthöft, 2010, Psychological approaches to origins and treatments of somatoform disorders, Annual Review of Clinical Psychology, 6, 257, 10.1146/annurev.clinpsy.121208.131505 · DOI
  172. Woelk, 2000, Comparison of St John's wort and imipramine for treating depression: randomised controlled trial, BMJ, 321, 536, 10.1136/bmj.321.7260.536 · DOI · Paper page
  173. Yirmiya, 1996, Endotoxin produces a depressive-like episode in rats, Brain Research, 711, 163, 10.1016/0006-8993(95)01415-2 · DOI · Paper page

Cited by

Items 201–300 of 528

Metadata

Authors
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2014-11-07
Volume
2014
Issue
11
Pages
CD010628-CD010628
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd010628.pub2
OpenAlex
W2139900098
Cited by
11,335
References
37
FWCI
540.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.